Rise In Respiratory Disorders Fueling The Growth Of The Market Due To Growing Need For Targeted Pulmonary Therapies: A Key Catalyst Accelerating Inhalable Biologics Market Growth in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Inhalable Biologics Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for inhalable biologics has experienced quick expansion in the recent past. The forecast predicts an increase from $2.79 billion in 2024 to $3.22 billion in 2025, which corresponds to a compound annual growth rate (CAGR) of 15.4%. Factors contributing to this growth during the historic period include an upsurge in worldwide incidence of respiratory diseases, soaring demand for non-invasive delivery methods, increased recognition of the advantages of biologics, and heightened biopharmaceutical research and investment.

Inhalable Biologics Market Size Forecast: What's the Projected Valuation by 2029?
It is anticipated that the inhalable biologics market will experience significant growth in the coming years, estimating to reach a market size of "$5.77 billion by 2029 exhibiting a compound annual growth rate (CAGR) of 15.7%. Factors contributing to this expansion in the forecast period include the accelerating rate of global ageing population, enhancements in healthcare facilities in burgeoning markets, rising regulatory support for biologics therapies, and an increase in cases of infectious respiratory diseases. During the forecast period, the market will notice trends such as advances in drug delivery systems, the amalgamation of smart inhaler technology, novel technologies in aerosol science, improvements in biologic drug formulations, and progress in nanoparticle-based carriers.

View the full report here:
https://www.thebusinessresearchcompany.com/report/inhalable-biologics-global-market-report

What Are the Drivers Transforming the Inhalable Biologics Market?
The surge in respiratory diseases is set to drive the growth of the inhalable biologics market. Such diseases, encompassing ailments of the lungs, airways, nasal passages, and other components of the respiratory system, primarily involve conditions like asthma, chronic obstructive pulmonary disease (COPD), and lung cancer, often exacerbated by escalating air pollution that exposes people to harmful particulate matter and other pollutants. Using inhalable biologics is advantageous for treating these conditions as they provide targeted therapy directly to the lungs, mitigating inflammation and enhancing lung function while minimizing systemic side effects. For instance, in June 2024, data from the government-run Australian Institute of Health and Welfare showed that COPD accounted for 3.6% of all diseases burden and half the burden of respiratory diseases in 2023. Hence, the rise in respiratory diseases plays a key role in bolstering the inhalable biologics market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24253&type=smp

Which Emerging Trends Are Transforming the Inhalable Biologics Market in 2025?
Major players in the inhalable biologics market are concentrating their efforts on developing advanced solutions, notably inhaled insulin, to enhance patient adherence and offer speedy control of blood glucose levels. Instead of using injections or insulin pumps, inhaled insulin is a type of insulin introduced into the bloodstream via inhalation through the lungs. This method entails breathing in a powdered or aerosolized version of insulin, which is absorbed by the lungs and promptly enters the bloodstream to aid in regulating blood sugar levels. For example, in February 2025, the Central Drugs Standard Control Organization granted regulatory approval to Cipla Limited, a pharmaceutical company based in India, for Afrezza, the quickest inhaled insulin on earth, offering a groundbreaking needle-free solution for type 1 and type 2 diabetic adults. This extremely quick-acting insulin works within 12 to 15 minutes of inhalation, accurately imitating the natural response to insulin intake during meals and enhancing control over blood sugar levels. The inhaled insulin provides a more comfortable replacement for multiple daily injections and is especially helpful for patients who fear injections, thus improving adherence to insulin therapy.

Which Segments in the Inhalable Biologics Market Offer the Most Profit Potential?
The inhalable biologics market covered in this report is segmented -

1) By Type: Peptides And Proteins, Vaccines, Monoclonal Antibodies, RNAi-Based Therapeutics, Other Types
2) By Dosage Form: Dry Powder Inhalers, Metered Dose Inhalers, Nebulizers, Other Dosage Forms
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Respiratory Diseases, Diabetes, Cancer, Other Applications

Subsegments:
1) By Peptides And Proteins: Insulin, Growth Hormones, Enzyme Replacement Therapies, Other Peptides And Proteins
2) By Vaccines: Influenza Vaccines, Other Respiratory Vaccines
3) By Monoclonal Antibodies: Respiratory Monoclonal Antibodies, Immunomodulatory Monoclonal Antibodies, Other Monoclonal Antibodies
4) By RNAi-Based Therapeutics: RNA-Based Drugs For Respiratory Diseases, Other RNAi-Based Therapeutics
5) By Other Types: Gene Therapies, Small Molecule Inhalable Drugs, Other Innovative Inhalable Biologics

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24253&type=smp

Which Firms Dominate the Inhalable Biologics Market by Market Share and Revenue in 2025?
Major companies operating in the inhalable biologics market are Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Medtronic PLC, Moderna Inc., Pfizer Inc. and BioNTech SE, Teva Pharmaceuticals, Baxter International, Lonza Group AG, CanSino Biologics Inc., Cipla Ltd., Insmed Incorporated, Kamada Pharmaceuticals, Vectura Group plc, F. Hoffmann‐La Roche Ltd, Iconovo AB, Synairgen plc, Ab Initio Pharma LLC, Nanopharm Ltd, Ocugen Inc., MannKind Corporation

Which Regions Offer the Highest Growth Potential in the Inhalable Biologics Market?
North America was the largest region in the inhalable biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inhalable biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24253

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.